InMed Pharmaceuticals (INM) Capital Expenditures (2019 - 2024)

InMed Pharmaceuticals' Capital Expenditures history runs 6 years deep, the most recent figure standing at $14201.0 for Q1 2024.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $14201.0 in Q1 2024; TTM through Jun 2024 was $9293.0, a 94.19% decrease from a year earlier, with the FY2024 full-year figure at $9293.0, down 94.19% from the prior year.
• Capital Expenditures advanced to $14201.0 in Q1 2024 per INM's latest filing, from -$1790.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $250000.0 in Q3 2021 and bottomed at -$256030.0 in Q4 2021.
• The 5-year median for Capital Expenditures is -$198.0 (2020), against an average of $17166.9.
• Biggest YoY gain for Capital Expenditures was 1684.82% in 2021; the steepest drop was 166353.25% in 2021.
• Year by year, Capital Expenditures stood at $154.0 in 2020, then slumped by 166353.25% to -$256030.0 in 2021, then surged by 97.85% to -$5507.0 in 2022, then jumped by 67.5% to -$1790.0 in 2023, then surged by 893.35% to $14201.0 in 2024.
• Per Business Quant, the three latest INM Capital Expenditures figures stand at $14201.0 (Q1 2024), -$1790.0 (Q4 2023), and -$3118.0 (Q3 2023).